

1 **New knowledge on the antiglycoxidative mechanism of chlorogenic acid**

2 Beatriz Fernandez-Gomez^a, Monica Ullate^a, Gianluca Picariello^b, Pasquale Ferranti^{b,c}, Maria
3 Dolores Mesa^d, Maria Dolores del Castillo ^{a*}.

4 ^aDepartment of Food Analysis and Bioactivity, Institute of Food Science Research (CIAL, CSIC-
5 UAM), Nicolas Cabrera 9, 28049 Madrid, Spain.

6 ^bIstituto di Scienze dell'Alimentazione (ISA), CNR, Via Roma 52, 83100 Avellino, Italy.

7 ^cDepartment of Agriculture, University of Naples "Federico II", Parco Gussone, Portici (NA)
8 80055, Italy.

9 ^dInstitute of Nutrition and Food Technology "José Mataix", University of Granada, Avenida del
10 Conocimiento s/n Armilla, 18100 Granada, Spain.

11
12 *Corresponding author: Maria Dolores del Castillo, Department of Food Analysis and Bioactivity,
13 Institute of Food Science Research (CIAL, CSIC-UAM), Nicolas Cabrera, 28049 Madrid, Spain.

14 Phone: +34 910017953

15 E-mail address: mdolores.delcastillo@csic.es

16
17 **Key words:** Advanced glycation end products (AGEs), chlorogenic acid, methylglyoxal,
18 glycoxidation reaction, antiglycoxidative effect.

19
20
21 **Abbreviations:** AGEs (advanced glycation end products), MGO (methylglyoxal), GO
22 (glyoxal), HCA (hydroxycinnamic acids), BSA (bovine serum albumin), CML (*N*^ε-
23 (carboxymethyl)lysine), CEL (*N*^ε-(carboxyethyl)lysine), AG (aminoguanidine), 5-CQA (5-*O*-
24 caffeoylquinic acid), 3-CQA (3-*O*-caffeoylquinic acid), CGA (3-*O*-caffeoylquinic acid)
25

32 **Abstract**

33 The mechanism of action of chlorogenic acid (CGA) on the formation of advanced glycation end-
34 products (AGEs) (glycooxidation reaction) was studied. Model systems composed of bovine serum
35 albumin (BSA) (1 mg mL⁻¹) and methylglyoxal (5 mM) under mimicked physiological conditions
36 (pH 7.4, 37 °C) were used to evaluate the antiglycoxidative effect of CGA (10 mM). The stability
37 of CGA under reaction conditions was assayed by HPLC and MALDI-TOF MS. The
38 glycooxidation reaction was estimated by analysis of free amino groups by OPA assay, spectral
39 analysis of fluorescent AGEs and total AGEs by ELISA, and colour formation by absorbance at
40 420 nm. Structural changes in protein were evaluated by analysis of phenol-bound to protein
41 backbone using the Folin reaction, UV-Vis spectral analysis and MALDI-TOF-MS, while
42 changes in protein function were measured by determining antioxidant capacity using the ABTS
43 radical cation decolourisation assay. CGA was isomerised and oxidised under our experimental
44 conditions. Evidence of covalent binding between BSA and multiple CGA and/or its derivatives
45 molecules (isomers and oxidation products) was found. CGA inhibited ($p < 0.05$) the formation
46 of fluorescents and total AGEs at 72 h of reaction by 91.2 and 69.7%, respectively. The binding
47 of phenols to BSA significantly increased ($p < 0.001$) its antioxidant capacity. A correlation was
48 found between free amino group content, phenol-bound to protein and antioxidant capacity.
49 Results indicate that CGA simultaneously inhibits the formation of potentially harmful
50 compounds (AGEs) and promotes the generation of neoantioxidant structures.

51

52

53

54

55

56

57 1. Introduction

58 Protein glycation includes an initial formation of Schiff's base, followed by intermolecular
59 rearrangement and conversion into Amadori products. They undergo further processing to form a
60 heterogeneous group of protein-bound moieties, such as cross-linking fluorescent (*e.g.*,
61 pentosidine) and non-fluorescent adducts (*e.g.*, *N*^ε-(carboxymethyl)lysine) (CML), *N*^ε-
62 (carboxyethyl)lysine (CEL)) called advanced glycation end products (AGEs).¹ Pathways of AGE
63 formation involve glucose autoxidation through the generation of α -oxoaldehydes, such as
64 methylglyoxal (MGO), 3-deoxyglucosone and glyoxal. MGO is a major precursor of AGEs,
65 especially CEL, which is capable of binding and modifying a number of proteins (glycoxidation
66 reaction), including bovine serum albumin (BSA), RNase A, collagen, lysozyme and lens
67 crystallins.^{2,3} Protein glycation is known to be involved in the pathogenesis of several age-related
68 disorders like diabetes, atherosclerosis, end-stage renal and neurodegenerative diseases.⁴

69 Inhibitors of AGEs formation might follow several mechanisms, such as aldose reductase,
70 antioxidant activity, reactive dicarbonyl trapping, sugar autoxidation inhibition and amino group
71 binding.⁵ The inhibition of AGE formation by synthetic aminoguanidine (AG) has been widely
72 documented. However, as AG treatment in type 1 diabetics has caused serious complications, the
73 search for natural AGE inhibitors is currently a challenge.⁶

74 Coffee and yerba mate are considered natural sources of abundant phenolic compounds that can
75 inhibit the formation of AGEs.^{7,8} The most representative phenolic acids in these foods are
76 chlorogenic acids (CGA), which commonly occur as 5-*O*-caffeoylquinic acid (5-CQA) or 3-*O*-
77 caffeoylquinic acid (3-CQA).^{9,10} The antiglycation activity of CGA has been associated to its
78 antioxidant and chelating characters, as well as to its ability to trap reactive dicarbonyl
79 compounds.^{8,11} This study aimed to obtain a better understanding of the antiglycoxidative
80 mechanism of action of CGA which is partly unknown. *In vitro* studies mimicking physiological
81 conditions were performed to achieve this goal.

82 2. Materials and methods

83 2.1 Materials

84 All chemicals and solvents were of analytical grade. Bovine serum albumin (BSA), phosphate
85 buffered saline (PBS), 3-*O*-caffeoylquinic acid (CGA), sodium azide, *ortho*-phthalaldehyde
86 (OPA), *N*^α-acetyl-L-lysine, Folin-Ciocalteu, 3,3', 5,5'-Tetramethylbenzidine (TMB) were from
87 Sigma–Aldrich (St. Louis, USA). Other chemicals and their suppliers were as follows: β-
88 mercaptoethanol (Merck, Hohenbrunn, Germany), methylglyoxal solution (MGO) and 2,2'-
89 azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (ABTS) (Fluka, Buchs,
90 Switzerland) and Bradford reagent for protein assay (Bio-Rad, München, Germany). The
91 Amicon® Ultra- 0.5 ml centrifugal filter unit fitted with an Ultracel®-30K regenerated cellulose
92 membrane (30 kDa cut-off) was from Merck Millipore Ltd. (Tullagreen, Cork, Ireland). Microtest
93 96-well plates made from high-quality polystyrene were purchased from Sarstedt AG & Co.
94 (Nümbrecht, Germany). The Costar® high binding 96-well EIA/RIA plate was from Corning
95 Incorporated (Corning, NY, USA). The Milli-Q water used in this study was obtained using a
96 purification system (Millipore, Molsheim, France).

97 2.2 Formation of CGA derivatives in control samples

98 2.2.1 HPLC analysis

99 Standard CGA before and after incubation at 37 °C for 24 h were compared to assess the chemical
100 stability of the compound under experimental conditions by reversed phase (RP) HPLC. A
101 modular chromatographer HP 1100 (Agilent Technologies, Paolo Alto, CA, USA) equipped with
102 a multi-waves UV-Vis detector was used to analyse samples. The stationary phase was a 250 x
103 2.1 mm i.d. C18 RP column, particle diameter 4 μm (Jupiter Phenomenex, Torrance, CA, USA).
104 Column temperature was maintained at 37 °C during the HPLC analyses. Separations were carried
105 out at a constant flow rate of 0.2 mL min⁻¹ applying a 5-60% linear gradient of solvent B
106 (acetonitrile/ 0.1% trifluoroacetic acid, TFA) over 60 min, after 5 min of isocratic elution at 5%
107 solvent B. Solvent A was 0.1% TFA in HPLC-grade water. For each run, 2.5 μg standard or
108 incubated CGA were diluted 10-fold with 0.1% TFA and injected using a Rheodyne® valve. The

109 HPLC separations were monitored at 280, 320 and 360 nm, while UV-Vis spectra (200-600 nm)
110 were recorded using a diode array detector.

111 2.2.2 MALDI-TOF-MS analysis

112 Mass spectra of CGA freshly prepared and incubated at 37 °C for 24 h were acquired on a
113 Voyager DE-Pro spectrometer (PerSeptive BioSystems, Framingham, Massachusetts) equipped
114 with a N₂ laser (λ = 337 nm) operating in both positive and negative reflector ion modes. The
115 matrix was 2,5-hydroxybenzoic acid (DHB) 10 mg mL⁻¹ in 50% acetonitrile. In the positive ion
116 mode, the matrix solution also contained 0.1% TFA. Spectra were acquired using Delay
117 Extraction technology at an accelerating voltage of 20 kV, exploring the *m/z* 150–1200 range.
118 Matrix ion signals were excluded by separately acquiring positive and negative spectra of DHB.
119 The mass range was externally calibrated with a mixture of standard polyphenols (Sigma, Milan,
120 Italy). Spectra were elaborated with Data Explorer 4.0.

121 2.3 *In vitro* glycoxidation of proteins

122 Model systems were composed of BSA at a final concentration of 1 mg mL⁻¹ in 0.01 M PBS
123 buffer (pH 7.4) added with sodium azide (0.05%) and MGO (5 mM). Glycoxidation model
124 systems were prepared in the presence or absence of the inhibitor (CGA 10 mM). Prior to
125 initiation of the glycoxidation reaction by addition of MGO, the pH values of all solutions were
126 measured at 25 °C using an electrode pH-meter (Metler Toledo, Spain) to ensure optimal and
127 equal conditions of reaction in all samples (pH=7.4). The model systems were incubated at 37 °C
128 for 192 h, and samples were taken after 24, 72, 96 and 192 h. The glycoxidation reaction was
129 stopped by cooling in an ice bath. All samples were prepared in triplicate. A control solution of
130 BSA was also included. The progress of the glycoxidation reaction was determined by analysing
131 free amino groups, AGEs and brown compounds.

132

133 2.3.1 Free amino groups

134 Free protein amino groups (both N-terminal and epsilon -NH₂ of lysine) were determined by the
135 OPA assay, following Go *et al.*¹² OPA reagent was freshly prepared by dissolving 10 mg of OPA
136 in 250 μ L of 95% (v/v) ethanol and adding 9.8 mL of 0.01 M PBS pH 7.4 and 20 μ L of β -
137 mercaptoethanol. The total volume of reaction was 250 μ L. The reaction was carried out in
138 transparent polystyrene 96-well microtest plate (No. 82.1581). Fluorescence was read after the
139 addition of OPA reagent on a microplate fluorescence reader Biotek SynergyTM HT (Biotek
140 Instruments, Highland Park, Winooski, USA) with excitation at 360 ± 40 nm and emission at 460
141 ± 40 nm. Fluorescence was read every 53 s for 15 min. Calibration curves were constructed using
142 standard solutions of *N* ^{α} -acetyl-L-lysine (0.025-1 mM). All measurements were performed in
143 triplicate, and data were expressed as μ g *N* ^{α} -acetyl-L-lysine equivalent per mg of protein.

144

145 2.3.2 AGEs

146 AGE formation was monitored by fluorescence spectrophotometry using a Biotek microplate
147 spectrophotometer at 360 ± 40 nm and 460 ± 40 nm as excitation and emission wavelengths,
148 respectively. No dilution was required for the glycoxidation model or the control systems. All
149 measurements were performed in triplicate.

150 The formation of total AGEs-BSA was measured by an indirect ELISA assay in samples
151 incubated for 72 h. A high affinity protein 96-well microplate was coated overnight (4° C) with
152 100 μ L of protein samples in 0.01 M phosphate buffer (pH 7.4) (5μ g mL⁻¹). Unbound proteins
153 were washed out with buffer PBS-T (PBS 0.01 M; Tween 0.05%), the wells were blocked with
154 gelatin 0.5% for 1 h at room temperature, then washed out with PBS-T, and the primary antibody
155 (dilution 1:1000) was added for 1 h. A polyclonal rabbit IG antibody which rose against AGEs
156 (AGE 102-0.2, Biologo, Kroshagen, Germany) was used as the primary antibody. After 1 h
157 incubation and five washing steps, the secondary horse radish peroxidise-conjugated mouse anti-
158 rabbit IgG antibody (ABIN376294, antibodies-online Inc., Suite, Atlanta) diluted 1:4000 in
159 washing buffer PBS-T was added, incubated for 1 h and washed again. Colour was developed
160 with TMB (100 μ L) and absorbance was read at 650 nm. Values were estimated by comparison

161 with a standard curve of glycated BSA (Methylglyoxal-AGE-BSA, CY-R2062, CircuLex™,
162 CycLex Co., Ltd, Nagano, Japan). All measurements were performed in triplicate, and results
163 were expressed as µg of AGEs-BSA per mg of protein.

164 2.3.3 Brown pigments

165 Formation of brown pigments in the samples was estimated by measuring absorbance at 420 nm
166 of the samples at 24, 72, 96 and 192 h, using microplate reader BioTek PowerWave™ XS.
167 Samples were analysed in triplicate.

168 2.4 Structural changes of proteins

169 Prior to analysis, the protein fraction of samples incubated at 37 °C for 72 h was isolated by
170 ultrafiltration. Samples (0.4 mL) were placed in the sample reservoir of an Amicon® Ultra- 0.5 mL
171 centrifugal filter unit fitted with an Ultracel®-30K regenerated cellulose membrane (30 kDa cut-
172 off) (Millipore Ltd., Ireland) and centrifuged at 14000 g for 40 min at room temperature. The
173 concentrated samples were recovered and diluted in PBS (0.4 mL). Protein concentration was
174 determined by the Bradford micromethod. The isolated protein fraction was used for structural and
175 functional characterisation.

176 2.4.1 UV-Vis spectra

177 A Biotek microplate UV-Vis spectrophotometer equipped with UV KC junior software (Biotek)
178 was used. The spectrum of fractionated samples was measured at 200-790 nm using a quartz 96-
179 well microplate.

180 2.4.2 Total phenolic compounds

181 Total phenolic content (TPC) of the isolated fraction incubated for 72 h was determined using the
182 Folin-Ciocalteu method as described by Singleton *et al.*¹³ adapted to a microplate reader. The
183 reduction reaction was carried out in 210 µL total volume in 96-well microplates (No. 82.1581).

184 A 10 μL of sample (appropriately diluted when necessary) was added to 150 μl volume of Folin-
185 Ciocalteu reagent (diluted 1:14, v/v) in Milli-Q water. After exactly 3 minutes, 4 mL of 75 g L^{-1}
186 sodium carbonate solution and 6 mL of water were mixed, and 50 μL of this mixture was added
187 to each well. Absorbance at 750 nm was recorded using a microplate reader BioTek
188 PowerWave™ XS. Calibration curves were constructed using standard solutions of CGA (0.1-1
189 mg L^{-1}), and results were expressed as $\mu\text{g CGA mL}^{-1}$.

190 2.4.3 MALDI-TOF-MS analysis

191 MALDI-TOF mass spectra of samples incubated for 72 h were acquired in the linear positive ion
192 mode using Voyager DE-Pro spectrometer (PerSeptive BioSystems, Framingham,
193 Massachusetts). The accelerating voltage was 25 kV. Sinapinic acid (10 mg L^{-1} in 50%
194 acetonitrile/TFA 0.1%) was used as the matrix. Spectra were externally calibrated using a
195 commercial protein mixture provided by the instrument manufacturer (PerSeptive Biosystems,
196 Framingham, Massachusetts).

197 2.5 Functionality changes in proteins

198 The antioxidant capacity of samples incubated for 72 h was estimated by the ABTS•⁺
199 decolourisation assay as described by Oki *et al.*¹⁴ 2,2'-azino-bis (3-ethylbenzothiazoline-6-
200 sulfonic) acid radical cations (ABTS•⁺) were produced by reacting 7 mM ABTS stock solution
201 with 2.45 mM potassium persulfate and allowing the mixture to stand in the dark at room
202 temperature for 12-16 h before use. The ABTS•⁺ solution (stable for 2 d) was diluted in 5 mM
203 PBS pH 7.4 (1:16 v/v) to an absorbance of 0.70 ± 0.02 at 734 nm. Each sample was dissolved in
204 phosphate buffer (5 mM, pH 7.4) at 0.1 mg L^{-1} . Thirty μL of test sample and 200 μL of diluted
205 ABTS•⁺ solution were mixed. Absorbance of the samples at 734 nm was measured at 10 min of
206 reaction using BioTek Power Wave™ XS microplate reader. CGA at concentrations of 0.015-0.2
207 mM was used for calibration.

208 2.6 Statistical analysis

209 Data were expressed as mean \pm standard deviation (SD). Analysis of Variance (more than 2
210 groups), one-way and two-way ANOVA followed by Bonferroni test, were applied to determine
211 differences between means. Differences were considered to be significant at $p < 0.05$.
212 Relationships between the analysed parameters were evaluated by computing Pearson linear
213 correlation coefficients setting the level of significance at $p < 0.001$.

214

215 **3. Results**

216 3.1 Formation of CGA derivatives

217 Fig. 1a compares the HPLC chromatograms of standard CGA before (lower panel) and after
218 incubation at pH 7.4, 37 °C for 24 h (upper panel). Peaks were assigned based on retention times
219 and UV-Vis spectra. Under our experimental conditions, CGA was converted into two isomers,
220 namely neochlorogenic acid (trans-5-*O*-Caffeoylquinic acid) and cryptochlorogenic acid (4-*O*-
221 Caffeoylquinic acid).

222 The MALDI-TOF-MS (Fig. 1b) demonstrated the co-occurrence of the hydroquinone and
223 quinone forms ($[M + H]^+$ m/z 353 and m/z 355, and $[M + Na]^+$ m/z 375 and m/z 377, respectively)
224 along with the dimeric adducts ($[2M + Na]^+$ m/z 729 and m/z 731), as assigned in the Table 1. No
225 CGA homopolymers were detected by either HPLC or MALDI-TOF-MS.

226

227 3.2 Progress of the glycooxidation reaction

228 The availability of free amino groups was obtained by OPA assay (Fig. 2). Incubation of BSA
229 alone at 37 °C for 192 h did not significantly affect ($p > 0.001$) the availability of free amino
230 groups, indicating the absence of inter-protein cross-linking events. Incubation in the presence of
231 MGO produced a significant decrease ($p < 0.001$) in BSA free amino groups during the incubation
232 period, suggesting that the glycooxidation reaction occurred. Interestingly, the addition of CGA to
233 the glycooxidation mixture (BSA+MGO) also caused a significant decrease ($p < 0.001$) in available
234 free amino groups throughout the whole incubation period. Available free amino groups also
235 decreased when BSA was incubated with CGA alone compared to the protein control and did not

236 significantly differ ($p > 0.001$) from those of the inhibition model composed of BSA, MGO and
237 CGA.

238 Fig. 3 illustrates the formation of fluorescent AGEs during 192 h of glycoxidation reaction. As
239 expected, the protein control (BSA alone) showed very low fluorescence intensity throughout the
240 experiment, due to intrinsic fluorescence caused by the presence of fluorescent amino acids in the
241 protein backbone. The reaction of BSA and MGO produced a significant formation ($p < 0.05$) of
242 fluorescent AGEs in a time dependent manner. The presence of CGA efficiently inhibited ($p <$
243 0.05) fluorescent AGE formation in the glycoxidation model system, while the reaction of BSA
244 and CGA caused a minor formation of fluorescent compounds. Further and more precise
245 information regarding the generation of total AGEs, both fluorescent and non-fluorescence
246 adducts, under our experimental conditions was obtained by indirect ELISA (Table 2). The results
247 are consistent with those obtained by fluorescence monitoring. BSA data are considered basal
248 values for all model systems. AGE generation was significantly ($p < 0.05$) inhibited by the
249 presence of CGA in the glycoxidation system.

250 Fig. 4 shows the generation of brown compounds. Absorbance values at 420 nm of mixtures
251 composed of BSA alone and BSA+MGO were very low and not significantly different ($p > 0.05$)
252 in any case. The presence of CGA in the model systems induced significant brown compound
253 formation in a time dependent manner. High and similar levels of browning ($p > 0.05$) were found
254 in model systems composed of CGA alone and BSA+CGA. The extent of brown compound
255 formation in samples composed of BSA, MGO and CGA was significantly lower ($p < 0.05$) than
256 in the other samples containing CGA.

257 3.3 Structural changes of protein

258 Since significant AGE formation was observed after 72 h of glycoxidation reaction (Fig. 3 and
259 Table 2), those samples were selected for further characterisation. As shown in Fig. 5a, fresh and
260 incubated (37 °C for 72 h) BSA solutions exhibited identical UV-Vis spectra, suggesting that no

261 structural modifications of proteins occurred following heating. Furthermore, the glycoxidation
262 reaction BSA+MGO did not alter the UV-Vis spectrum compared to fresh BSA. In contrast, the
263 protein fraction isolated from the glycoxidation mixture with CGA showed a very different
264 spectrum than that found for the control (BSA) and was very similar to the spectrum of BSA
265 incubated with CGA.

266 Total phenolic content of the samples incubated at pH 7.4, 37 °C for 72 h is shown in Fig. 5b. As
267 expected, significant levels ($p < 0.05$) of phenolic compounds were detected in the protein
268 fractions isolated from the CGA model systems, namely BSA + CGA and BSA + MGO + CGA.

269 MALDI-TOF-MS analysis was performed to confirm the formation of covalent bindings of CGA
270 to the protein backbone at 72 h (Fig. 6). In the spectra corresponding to BSA incubated with
271 MGO, the characteristic peak of BSA was clearly visible with variable mass increases (Fig. 6b).
272 Greater mass shifts were observed when BSA was incubated with CGA either in the absence (Fig.
273 6c) or presence of MGO (Fig. 6d). The mass data suggested that, BSA binds several molecules of
274 CGA and its derivatives in addition to the MGO in these samples, forming a heterogeneous
275 mixture of protein conjugates as reflected by the broadening of BSA peaks (Fig. 6c and 6d).

276 3.4 Changes of protein function

277 The antioxidant capacity of the isolated protein fractions obtained from samples incubated at 37
278 °C for 72 h is shown in Fig. 7. The reaction with MGO did not modify the antioxidant capacity of
279 BSA. The addition of CGA to reaction mixtures caused the formation of compounds (MW > 30
280 kDa) which had antioxidant capacity values of 303.07 and 309.89 $\mu\text{g eq-CGA mL}^{-1}$ for model
281 system composed of BSA+MGO+CGA and BSA+CGA, respectively.

282 3.5. Correlation between parameters

283 A significant negative correlation ($r=-0.754$, $p < 0.001$) between data corresponding to free amino
284 groups and antioxidant capacity was observed for samples incubated at 37 °C for 72h. A

285 significant negative correlation ($r=-0.689$, $p < 0.001$) was also found between free amino groups
286 and total phenolic content.

287 4. Discussion

288 In this work we observed that structural changes in CGA produced *in vitro* under mimicked
289 physiological conditions may contribute to the antiglycoxidative properties of this compound.
290 Isomerisation of CGA (3-*O*-caffeoylquinic acid) was induced at pH 7.4 and 37 °C. The formation
291 of neochlorogenic (trans-5-*O*-caffeoylquinic acid) and cryptochlorogenic (4-*O*-caffeoylquinic
292 acid) acid from CGA under similar reaction conditions has previously been reported.^{15,17} CGA
293 derivatives such as oxidation products and isomers might be able to act as substrate or/and
294 precursors of the Maillard and polymerisation reactions.¹⁸ The formation of mono-quinones and
295 dimer quinones was also observed in CGA incubated at pH 7.4 and 37 °C for 24 h. This is in
296 agreement with the non-enzymatic oxidation of CGA described by Rawel et al.¹⁹

297 Brown compounds may be formed by the Maillard reaction, oxidation of phenols and phenol
298 polymerisation.¹⁸ Our data suggest that the Maillard and phenol oxidation reactions are the main
299 pathways leading to the formation of brown compounds under our experimental conditions. Both
300 CGA and its derivatives are able to react with BSA via the Maillard reaction. However, further
301 studies are needed to determine the chemical nature of new-formed coloured compounds.

302 The observed decrease in the formation of AGEs in the presence of CGA demonstrates the
303 antiglycative activity of this compound. On the other hand, our results suggest conjugation of
304 CGA or its derivatives to free amino groups. A significant negative correlation between content
305 of free amino groups and phenolic compounds was found. These results are in agreement with
306 Rawel et al.²⁰ who reported a decrease in lysine residues due to the reaction of BSA and CGA at
307 room temperature for 24 h. CGA isomers and quinones can interact with proteins forming non-
308 covalent and covalent bonds through the Maillard Reaction¹⁸. Phenolics bind highly nucleophilic
309 thiol, amine groups and hydrophobic aromatic groups of proteins.²¹ Three potential types of non-
310 covalent interactions between hydroxycinnamic acids and proteins have been proposed: hydrogen,

311 hydrophobic, and ionic binding.²² Prigent et al.²¹ found that oxidised CGA induced covalent
312 modification of α -lactalbumin and lysozyme.

313 Soft ionization MS techniques such as MALDI are useful to evaluate the hydroxycinnamates
314 (HCA) covalently bound to proteins.²⁰ MALDI-TOF-MS data suggest the formation of
315 neoformed protein-phenol conjugates, inducing MS increments of 1.7 and 1.3 kDa in samples
316 corresponding to BSA+CGA and BSA+CGA+MGO, respectively. The increase of molecular
317 mass is indicative of covalent binding between CGA and/or its derivatives to the protein structure.
318 Data on MALDI-TOF-MS support the data obtained on free amino groups, phenolic compounds
319 and UV-Vis spectra.

320 The formation of complexes by covalent binding of other reactive phenols such as quercetin to
321 BSA exhibiting antioxidant potential have been previously reported.^{23,24} Quercetin and CGA share
322 a high binding affinity for BSA. The ability of these two compounds to form covalent complexes
323 polyphenol-BSA under physiological conditions has been demonstrated.^{25,26} Our results show that
324 CGA causes the neoformation of molecules with antioxidant capacity.

325 Gugliucci et al.⁸ previously associated the inhibitory capacity against formation of fluorescent
326 AGEs of *Ilex paraguariensis* extracts to the presence of CGA. The inhibitory capacity of CGA
327 was linked to its antioxidant character, chelating properties to transition metals ions, quenching of
328 carbonyl radical species and AGE crosslinking.²⁷⁻²⁹ Other authors have also shown the ability of
329 CGA to inhibit *in vitro* BSA glycation induced by fructose and glucose and the formation of AGE
330 crosslinking from collagen.¹¹ We have recently reported that MGO is effectively trapped by CGA
331 with an IC_{50} of 0.14 mg mL⁻¹.³⁰ In addition to this mechanism, we propose for the first time a
332 relationship between the high binding capacity of CGA to BSA and its antiglycoxidative
333 mechanism of action. The covalent interactions suggest MGO and GCA are competing for reactive
334 protein sites (free amine group). This effect prevents MGO from binding to BSA resulting in an
335 effective decrease in AGE formation.

336 Coffee is the major source of CGA on the worldwide diet. CGA from coffee has shown a high
337 bioavailability in humans.³¹ Previous studies suggest that consumption of coffee acutely increases
338 the concentrations of phenolic compounds in LDL cholesterol particles and platelets, increases *ex*
339 *vivo* resistance to LDL oxidation, and reduces platelet aggregation in healthy volunteers.^{32,33}
340 These results support formation of antioxidant polyphenol-protein complexes *in vivo* and *ex vivo*
341 with health promoting properties. Formation of polyphenol-protein complexes *in vivo* is feasible
342 and it may be associated to a reduction of risk of diabetes complications such as cardiovascular
343 disease.

344 In summary, the covalent conjugation of CGA and its derivatives (isomers and quinones) to side-
345 chains of protein lysine residues reduces the formation of potentially harmful compounds, also
346 called AGEs, and promotes the generation of antioxidant structures, which may be beneficial for
347 human health.

348

349 **Acknowledgements**

350 This study was funded by the projects: AGL2010-17779 and IT2009-0087. B Fernandez is
351 grateful for a FPI-predoc grant from the Ministry of Economy and Competitiveness (Spain).

352

353 **References**

- 354 1. R. B. Nawale, V.K. Mourya and S. B. Bhise, Non-enzymatic glycation of proteins: a cause for
355 complications in diabetes, *Indian J. Biochem. Bio.*, 2006, **43**, 337-344.
- 356 2. Z. Kender, P. Torzsa, K. V. Grolmusz, A. Patócs, A. Lichthammer, M. Veresné Bálint, K.
357 Rácz and P. Reismann, The role of methylglyoxal metabolism in type-2 diabetes and its
358 complications, *Orv. Hetil*, 2012, **153**, 574-585.
- 359 3. K. V. Tarwadi and V. V. Agte, Effect of micronutrients on methylglyoxal-mediated in vitro
360 glycation of albumin, *Biol. Trace Elem. Res.*, 2011, **143**, 717-725.
- 361 4. N. Ahmed, Advanced glycation endproducts-role in pathology of diabetic complications,
362 *Diabetes Res. Clin. Pr.*, 2005, **67**, 3-21.
- 363 5. I. Bousová, J. Martin, L. Jahodár, J. Dusek, V. Palicka and J. Drsata, Evaluation of
364 in vitro effects of natural substances of plant origin using a model protein glycooxidation. *J*
365 *Pharmaceut. Biomed.*, 2005, **37**, 957-962.
- 366 6. P. J. Thornalley, Use of aminoguanidine (Pimagedine) to prevent the formation of advanced
367 glycation endproducts, *Arch. Biochem. Biophys.*, 2003, **419**, 31-40.
- 368 7. E. Verzelloni, D. Tagliazucchi, D. Del Rio, L. Calani and A. Conte, Antiglycative and
369 antioxidative properties of coffee fractions, *Food Chem.*, 2011, **124**, 1430-1435.
- 370 8. A. Gugliucci, D. H. Markowicz Bastos, J. Schulze and M. Ferreira Souza, Caffeic and
371 chlorogenic acids in *Ilex paraguariensis* extracts are the main inhibitors of AGE generation
372 by methylglyoxal in model proteins, *Fitoterapia*, 2009, **80**, 339-344.
- 373 9. M. N. Clifford, Chlorogenic acids and other cinnamates—nature, occurrence, dietary burden,
374 absorption and metabolism, *J. Agric. Food Chem.*, 2000, **80**, 1033-1043.
- 375 10. S. Meng, J. Cao, Q. Feng, J. Peng and Y. Hu, Roles of chlorogenic acid on regulating glucose
376 and lipids metabolism: a review, *Evid. Based Complement. Alternat. Med.*, 2013, DOI:
377 10.1155/2013/801457.

- 378 11. J. Kim, I. H. Jeong, C. S. Kim, Y. M. Lee, J. M. Kim and J. S. Kim, Chlorogenic acid inhibits
379 the formation of advanced glycation end products and associated protein cross-linking, *Arch.*
380 *Pharmacol. Res.*, 2011, **34**, 495-500.
- 381 12. K. Go, R. Garcia and F. J. Villarreal, Fluorescent method for detection of cleaved collagens
382 using *O*-phthaldialdehyde (OPA), *J. Biochem. Biophys. Methods*, 2008, **70**, 878-882.
- 383 13. V. L. Singleton, R. Orthofer and R. M. Lamuela-Reventós, Analysis of total phenols and other
384 oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent, *Methods Enzymol.*,
385 1999, **299**, 152-178.
- 386 14. T. Oki, M. Masuda, S. Furuta, Y. Nishiba, N. Terahara and I. Suda, Involvement of
387 anthocyanins and other phenolic compounds in radical-scavenging activity of purple-fleshed
388 sweet potato cultivars, *J. Food Sci.*, 2002, **67**, 1752-1756.
- 389 15. S. Li and C.T. Ho, Stability and transformation of bioactive polyphenolic components of herbs
390 in physiological pH. In *Herbs: Challenges in Chemistry and Biology*, ed. American Chemical
391 Society, 2006, ch. 18, pp. 240-253.
- 392 16. S. Deshpande, R. Jaiswal, M.F. Matei and N. Kuhnert. Investigation of acyl migration in
393 mono- and dicaffeoylquinic acids under aqueous basic, aqueous acidic, and dry roasting
394 conditions, *J. Agric. Food Chem.*, 2014, **37**, 9160-9170.
- 395 17. C. Xie, K. Yu, D. Zhong, T. Yuan, F. Ye, J. A. Jarrell, A. Millar and X. Chen, Investigation
396 of isomeric transformations of chlorogenic acid in buffers and biological matrixes by
397 ultraperformance liquid chromatography coupled with hybrid quadrupole/ion
398 mobility/orthogonal acceleration time-of-flight mass spectrometry. *J. Agric. Food Chem.*,
399 2011, **59**, 11078-11087.
- 400 18. Z. Budryn and D. Rachwal-Rosiak, Interactions of hydroxycinnamic acids with proteins and
401 their technological and nutritional implications, *Food Rev. Int.*, 2013, **29**, 217-230.
- 402 19. H. M. Rawel and S. Rohn, Nature of hydroxycinnamate-protein interactions, *Phytochem. Rev.*,
403 2010, **9**, 93-109.
- 404 20. H. M. Rawel, S. Rohn, H. P. Kruse and J. Kroll, Structural changes induced in bovine serum
405 albumin by covalent attachment of chlorogenic acid, *Food Chem.*, 2002, **78**, 443-455.

- 406 21. S. V. Prigent, A. G. Voragen, A. J. Visser, G. A. van Koningsveld and H. Gruppen, Covalent
407 interactions between proteins and oxidation products of caffeoylquinic acid (chlorogenic acid),
408 *J. Sci. Food Agric.*, 2007, **87**, 2502-2510.
- 409 22. T. Dan , L. Hui-Jun, L. Ping , W. Xiao-Dong and Q. Zheng-Ming, Interaction of bioactive
410 components caffeoylquinic acid derivatives in chinese medicines with bovine serum albumin,
411 *Chem. Pharm. Bull.*, 2008, **56**, 360-365.
- 412 23. R. Sascha, H. M. Rawel and J. Kroll, Antioxidant activity of protein-bound quercetin, *J. Agric.*
413 *Food Chem.*, 2004, **52**, 4725-4729.
- 414 24. X. Y. Dong, H. F. Yao, F. Z. Ren and H. Jing, Characteristics and antioxidant activity of
415 bovine serum albumin and quercetin interaction in different solvent systems, *Spectrosc. Spect.*
416 *Anal.*, 2014, **34**, 162-166.
- 417 25. Y. Ni, X. Zhangb and S. Kokotc, Spectrometric and voltammetric studies of the interaction
418 between quercetin and bovine serum albumin using warfarin as site marker with the aid of
419 chemometrics, *Food Chem.*, 2006, **99**, 191-203.
- 420 26. L. Trnkova, I. Bousova, V. Kubicek and J. Drsata, Binding of naturally occurring
421 hydroxycinnamic acids to bovine serum albumin, *Natural Science*, 2010, **6**, 563-570.
- 422 27. H. Y. Kim and K. Kim, Protein glycation inhibitory and antioxidative activities of some plant
423 extracts in vitro, *J. Agric. Food Chem.*, 2003, **51**, 1586-1591.
- 424 28. S. Sang, X. Shao, N. Bai, C. Y. Lo, C. S. Yang and C. T. Ho, Tea polyphenols
425 (-)epigallocatechin-3-gallate: A new trapping agent of reactive dicarbonyl species, *Chem. Res.*
426 *Toxicol.*, 2007, **20**, 1862-1870.
- 427 29. C. H. Wu and G. C. Yen, Inhibitory effect of naturally occurring flavonoids on the formation
428 of advanced glycation endproducts, *J. Agric. Food Chem.*, 2005, **53**, 3167-3173.
- 429 30. M. Mesías, M. Navarro, N. Martínez-Saez, M. Ullate, M. D. del Castillo, F. J. Morales,
430 Antiglycative and carbonyl trapping properties of the water soluble fraction of coffee
431 silverskin, *Food Res. Int.*, 2014, **62**, 1120-1126.
- 432 31. A. Farah, M. Monteiro, C. M. Donangelo and S. Lafay, Chlorogenic acids from green coffee
433 extract are highly bioavailable in humans, *J. Nutr.*, 2008, **12**, 2309-2315.

434 32. F. Natella, M. Nardini, F. Belevli, P. Pignatelli, S. Di Santo, A. Ghiselli, F. Violi and C.
435 Scaccini, Effect of coffee drinking on platelets: inhibition of aggregation and phenols
436 incorporation, *Br. J. Nutr.*, 2008, **100**, 1276–1282.

437 33. F. Natella, M. Nardini, F. Belevli and C. Scaccini, Coffee drinking induces incorporation of
438 phenolic acids into LDL and increases the resistance of LDL to *ex vivo* oxidation in humans,
439 *Am. J. Clin. Nutr.*, 2007, **86**, 604-609.

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461 **Table 1:** MALDI-TOF MS assignments of CGA derivatives.

<i>m/z</i>	Assignment
353.5	[CGA*+H] ⁺ quinone
355.5	[CGA+H] ⁺
375.3	[CGA+Na] ⁺ quinone
377.5	[CGA+Na] ⁺
393.3	[CGA+K] ⁺
399.3	[CGA+2Na] ⁺
415.3	[CGA+Na+K] ⁺
531.4	DHB (matrix) adducts
547.4	DHB (matrix) adducts
551.4	DHB (matrix) adducts
729.6	[CGA+CGAquinone+Na] ⁺
751.6	[CGA+CGAquinone+2Na] ⁺
775.6	[CGA+CGAquinone+3Na] ⁺

*CGA includes the isomers of chlorogenic acid that are undistinguishable by mass spectrometry.

462

463

464

465

466

467

468

469

470

471

472

473

474

475 **Table 2:** Content of total AGEs in samples corresponding to control (BSA), BSA with MGO
 476 (BSA+MGO), BSA with MGO and CGA (BSA+MGO+CGA) and BSA with CGA (BSA+CGA)
 477 incubated at pH 7.4 and 37 °C for 72 h. Concentrations assayed were 1mg mL⁻¹ BSA, 5 mM MGO
 478 and 10 mM CGA. BSA data are considered as initial values.

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501


502

	Incubation time (h)
	72
BSA	1.01 ± 0.08 ^b
BSA+MGO	1.68 ± 0.13 ^a
BSA+MGO+CGA	0.51 ± 0.08 ^c
BSA+CGA	0.84 ± 0.19 ^{b,c}

Each value represents the mean (n = 9) ± standard deviation. Different letters denote significant differences (p < 0.05) between samples of the same column.


503 **Fig. 1:** (a) RP-HPLC chromatograms of CGA (10 mM) incubated at pH 7.4, 37 °C during 24 h
 504 (upper panel) and freshly prepared (lower panel). Peak 1: neochlorogenic acid; Peak 2:
 505 cryptochlorogenic acid; Peak 3: chlorogenic acid (b) MALDI-TOF spectra of incubated at pH 7.4,
 506 37 °C for 24 h (upper panel) and freshly prepared CGA (lower panel).

507 a



508

509 b



510

511

512

513 **Fig. 2:** Changes in the content of free amino groups in samples of control (BSA), BSA with MGO


514 (BSA+MGO), BSA with MGO and CGA (BSA+MGO+CGA) and BSA with CGA (BSA+CGA)

515 incubated at pH 7.4, 37 °C at different times during 192 h. Concentrations assayed were 1 mg mL⁻¹

516 ¹ BSA, 5 mM MGO and 10 mM CGA. Data are means of triplicate analyses (n=9). Error bars

517 denote the relative standard deviation. Different letters indicate significant differences (p < 0.001)

518 within model systems at different times. BSA data are considered as references.



519

520

521

522

523

524

525


526

527

528


529

530 **Fig. 3:** Time-course of fluorescent AGE formation in samples of control (BSA), BSA with MGO
 531 (BSA+MGO), BSA with MGO and CGA (BSA+MGO+CGA) and BSA with CGA (BSA+CGA)
 532 incubated at pH 7.4 and 37 °C at different times during 192 h. Concentrations assayed were 1 mg
 533 mL⁻¹ BSA, 5 mM MGO and 10 mM CGA. Data represent relative fluorescence units (RFU) (λ_{exc}
 534 360 nm, λ_{em} 440 nm). Bars represent mean values (n=9) and error bars represent standard
 535 deviation. Different letters denote significant differences ($p < 0.05$) within model systems at the
 536 different times.



537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549


550 **Fig. 4:** Time-course of brown compound formation from control (BSA), BSA with MGO
 551 (BSA+MGO), BSA with MGO and CGA (BSA+MGO+CGA), BSA with CGA (BSA+CGA) and
 552 CGA control (CGA) incubated at pH 7.4, 37 °C for 192 h. Concentrations assayed were 1 mg mL⁻¹
 553 BSA, 5 mM MGO and 10 mM CGA. Data represent relative absorbance at 420 nm at different
 554 time points. Bars represent mean values (n=9) and error bars represent standard deviation.
 555 Different letters denote significant differences (p < 0.05) within model systems at the different
 556 times.
 557



558
 559
 560
 561
 562
 563
 564
 565
 566


567 **Fig. 5:** (a) UV-Vis absorption spectra and (b) content of phenol compounds bound to BSA isolated
568 from samples corresponding to control (BSA), BSA with MGO (BSA+MGO), BSA with MGO
569 and CGA (BSA+MGO+CGA), BSA with CGA (BSA+CGA) and CGA control (CGA) incubated
570 at pH 7.4 and 37 °C for 72 h. Concentrations assayed were 1 mg mL⁻¹ BSA, 5 mM MGO and 10
571 mM CGA. Bars represent mean values (n=9) and error bars represent standard deviation. Different
572 letters denote significant differences (p < 0.001) between means.

573 **a**



574


575 **b**



576


577

578 **Fig. 6:** MALDI-TOF spectra of BSA control (a), BSA with MGO (b), BSA with CGA (c) and
579 BSA with MGO and (d) incubated at pH 7.4 and 37 °C for 72h. Concentrations assayed were 1
580 mg mL⁻¹ BSA, 5 mM MGO and 10 mM CGA.



581

582 **Fig. 7:** Antioxidant capacity of the high molecular weight fractions isolated from samples of
583 control (BSA), BSA with MGO (BSA+MGO), BSA with MGO and CGA (BSA+MGO+CGA),
584 BSA with CGA (BSA+CGA) and CGA control (CGA) incubated at at pH 7.4 and 37 °C for 72 h.
585 Concentrations assayed were 1 mg mL⁻¹ BSA, 5 mM MGO and 10 mM CGA.. Data are expressed
586 as µg eq-CGA mL⁻¹. Bars represent mean values (n=9) and error bars represent standard deviation.
587 Different letters denote significant differences (p < 0.001) between means.



588

589

590

591